Click here to check out calendar of events for this month.
CMSC News:
For a complete listing of CMSC News, please click here.
CMSC Community News:
For a complete listing of CMSC Community News, please click here.
CMSC INForMS (Industry News for MS):
For a complete listing of CMSC Industry News for MS, please click here.
- January 27, 2012 - FDA Changes Tysabri Label to Include Anti-JC Virus Antibody Status as a
PML Risk Factor 
- January 26, 2012 - ASCEND Study to Evaluate the Effectiveness of TYSABRI® (natalizumab) as a Treatment for Secondary-Progressive Multiple Sclerosis
- January 25, 2012 - Merck Serono Receives European Approval to Expand Use of Rebif® in Patients with Early Multiple Sclerosis
- January 25, 2012 - EMA Seeks Industry Comments On IFN-Beta Draft Guideline
- January 23, 2012 - MS LifeLines Earns J.D. Power and Associates Call Center Certification for Customer Service Excellence in Providing Support Services to the MS Community
- January 20, 2012 - European Medicines Agency Commences Safety Review of Gilenya
- January 19, 2012 - Adeona Announces Initiation of Phase II Clinical Trial of Trimesta for Cognitive Dysfunction in Multiple Sclerosis
- January 3, 2012 - Advanced Magnetic Resonance Imaging Technology Suggests Axonal Repair in Multiple Sclerosis Patients Treated with COPAXONE®
- December 21, 2011 - MorphoSys Initiates Phase 1b Clinical Trial with MOR103 in Patients with Multiple Sclerosis
- December 20, 2011 - FDA Drug Safety Communication: Safety review of a reported death after the first dose of Multiple Sclerosis drug Gilenya (fingolimod)
- December 20, 2011 - Genzyme Reports Top-line Results for TENERE Study of Oral Teriflunomide in Relapsing Multiple Sclerosis
- December 12, 2011 - Findings could change way MS is diagnosed, treated
- December 8, 2011 - From the Front Lines: MS Research to Follow in 2012
- December 7, 2011 - From the Outside In: Mayo Clinic Collaboration Finds Multiple Sclerosis Often Starts in Brain's Outer Layers
- December 3, 2011 - World First in MS Fight
- November 18, 2011 - Merck Serono: CHMP Gives Positive Opinion for Extended Indication for Rebif® to Treat Patients With Early Signs of Multiple Sclerosis
- November 14, 2011 - Genzyme Announces Successful Phase III Results for Alemtuzumab (LEMTRADATM*) in Multiple Sclerosis
- November 9, 2011 - Nuron Biotech Initiates Phase 3 Study of Proprietary Recombinant Human Interferon Beta-1b NU100 in Relapsing Remitting Multiple Sclerosis
- November 3, 2011 - Avanir Pharmaceuticals Announces Enrollment of First Patient in PRIME Study of AVP-923 in Central Neuropathic Pain in Multiple Sclerosis
- November 2, 2011 - Geron Announces Presentation At ECTRIMS/ACTRIMS
- November 2, 2011 - Data on Relapsing-Remitting Multiple Sclerosis Detailed by Researchers at Novartis Pharmaceuticals
- October 27, 2011 - Acorda Therapeutics Announces Data on AMPYRA® Presented at 5th Joint Triennial Congress of ECTRIMS and ACTRIMS
- October 27, 2011 - GW Pharmaceuticals plc - Phase III data on efficacy and tolerability of Sativex® in MS spasticity presented at ECTRIMS
- October 26, 2011 - Biogen Idec Announces Positive Top-Line Results from Second Phase 3 Trial Investigating Oral BG-12 (Dimethyl Fumarate) in Multiple Sclerosis
- October 22, 2011 - Alemtuzumab (LemtradaTM*) Significantly Reduces Relapses in Multiple Sclerosis vs Interferon Beta-1a in a Phase III Study
- October 22, 2011 - Biogen Idec and Abbott Present Positive Data for Daclizumab HYP from Select Phase 2b Trial at ECTRIMS/ACTRIMS
- October 21, 2011 - Athersys and Fast Forward, LLC Enter Collaboration to Support Development of MultiStem to Treat Multiple Sclerosis
- October 21, 2011 - BAYER – New data confirm the benefits of early and first line treatment with Betaferon in Multiple Sclerosis (MS)
- October 21, 2011 - Oral BG-12 (Dimethyl Fumarate) Significantly Reduced Multiple Sclerosis (MS) Relapses and Disability Progression in Define Phase 3 Clinical Trial
- October 20, 2011 - Oral Therapy Teriflunomide (AubagioTM(*)) Significantly Reduces Relapses Leading to Hospitalization of Patients with Multiple Sclerosis
- October 20, 2011 - Protaffin AG Announces Preclinical Data in Multiple Sclerosis for MCP-1 Decoy Program
- October 20, 2011 - Treatment with COPAXONE in Multiple Sclerosis Demonstrated Remyelination and Neuroprotective Effects in a Preclinical Setting
- October 20, 2011 - Phase II Study Showed Ocrelizumab Maintained Significant Reduction in Disease Activity for Multiple Sclerosis Patients for Almost Two Years
- October 19, 2011 - EMD Serono and Fast Forward Commit $3 Million for Multiple Sclerosis
- October 19, 2011 - Data about Early Use and Long-Term Benefit of TYSABRI Presented at 5th Joint Triennial Congress of ECTRIMS and ACTRIMS
- October 19, 2011 - Active Biotech: Investigational Laquinimod Demonstrates Its Potential as a New Oral Treatment for RRMS
- October 19, 2011 - Research on Multiple Sclerosis Described by Scientists at Pfizer
- October 7, 2011 - Randomized Trial of Oral Teriflunomide for Relapsing Multiple Sclerosis
- October 4, 2011 - Merck Serono and Ono Pharmaceutical Form Collaborations to Develop Oral Multiple Sclerosis Drug and Cancer Immunotherapy
- October 1, 2011 - Amino sugar may help treat MS symptoms
- September 19, 2011 - Merck Serono Acquires Rights to PI-2301 Program for Multiple Sclerosis
- September 14, 2011 - Multiple Sclerosis Association of America and National Disability Institute Launch a Four-Part Webinar Series on Financial Wellness for the Multiple Sclerosis Community
- September 6, 2011 - AB Science Announces Recruitment of First Patient in Phase 3 Study of masitinib in Progressive Multiple Sclerosis
- August 24, 2011 - BOTOX® (onabotulinumtoxinA) Receives U.S. FDA Approval for the Treatment of Urinary Incontinence in Adults with Neurological Conditions Including Multiple Sclerosis and Spinal Cord Injury
- August 16, 2011 - Inhibikase Therapeutics Receives FDA Clearance for Phase II Trial of IkT-001 to Treat JC Virus Infection, the Cause of Progressive Multifocal Leukoencephalopathy (PML) in Multiple Sclerosis Patients
- August 10, 2011 - Acorda Therapeutics Announces Allowance of Second U.S. Patent Application for AMPYRA Covering Methods of Use for Improving Walking in Multiple Sclerosis
- August 9, 2011 - Biogen Idec and Abbott Announce Positive Top-Line Results from the First Registrational Trial for Daclizumab HYP in Relapsing-Remitting Multiple Sclerosis
- August 8, 2011 - Allergan's BOTOX Receives A Positive Opinion in Fourteen European Countries for Urinary Incontinence in Patients with MS or Spinal Cord Injury
- August 5, 2011 - Campaigners call for rethink on drug ban; Watchdog blocks use of MS pill
- August 4, 2011 - New Mobile App for Patients with Multiple Sclerosis and Diabetes
- August 2, 2011 - FDA Approves Fingolimod Update in Prescribing Information
- August 2, 2011 - Actelion's selective S1P1 receptor agonist ponesimod successful in mid-stage trial for multiple sclerosis - Ponesimod to proceed to Phase III final stage of clinical development
- August 1, 2011 - Results of Phase III Bravo Trial Reinforce Unique Profile of Laquinimod for Multiple Sclerosis Treatment
- July 27, 2011 - Biogen Idec Strengthens MS ActiveSource® for People with Multiple Sclerosis
- July 27, 2011 - Evergreen Neurologist Co-Authors Key Study on Multiple Sclerosis Treatment Cost
- July 27, 2011 - NextGen Sciences launches multiplex protein CSF biomarker assay for multiple sclerosis
- July 25, 2011 - Biogen Idec Receives Conditional Approval in the European Union for FAMPYRA to Improve Walking in Adults with Multiple Sclerosis
- July 20, 2011 - Daval International Announces Completion of Phase II Trial for the Treatment of Bladder Dysfunction With AIMSPRO® in Secondary Progressive Multiple Sclerosis
- July 19, 2011 - Start of in-Patient Clinical Trials With NT-KO-003, the First Neuroprotective Drug for Multiple Sclerosis Without Immunosuppressive Effects
- July 11, 2011 - Sanofi Reports Positive Top-Line Results from First Phase 3 Study of Alemtuzumab (Lemtrada®) in Multiple Sclerosis
- June 30, 2011 - Merck Serono and Fast Forward Announce Recipients of Funding for Multiple Sclerosis Research
- June 29, 2011 - Merck Serono Submits Application for Extension of Indication for Rebif® in Europe
- June 22, 2011 - Merck Serono: Regulatory Update on Cladribine Tablets
- June 17, 2011 - Study Finds Shingles May Be Related to Elevated Risk of Multiple Sclerosis
- June 8, 2011 - Sativex approved in Denmark for the treatment of spasticity due to Multiple Sclerosis
- June 7, 2011 - Biogen Idec Receives Approval in the European Union for Avonex Pen
- June 6, 2011 - New Clinical Data Analysis of AMPYRA® (Dalfampridine) Shows Improvement of Patient-Reported Walking Ability across a Range of Walking Impairment
- June 6, 2011 - Biogen Idec Reports Positive Data from AVONEX Dose Titration Study at 2011 Annual Meeting of the Consortium of Multiple Sclerosis Centers
- June 2, 2011 - A Promising New Approach to Autoimmune Diseases
- June 2, 2011 - Teva Completes Enrollment in Phase III Multiple Sclerosis Trial Evaluating Glatiramer Acetate Three Times Weekly
- May 27, 2011 - Patients test new MS drug [Sentinel, The (Stoke-on-Trent, England)]
- May 26, 2011 - Sativex Approved in Germany for the Treatment of Spasticity Due to Multiple Sclerosis
- May 24, 2011 - Biogen Idec Launches Women in MS Educational Initiative
- May 20, 2011 - Acorda Therapeutics Statement on CHMP Positive Opinion on Marketing Authorization Application for FAMPYRA in Europe
- May 16, 2011 - Biogen Idec Receives Approval for Fampyra in Australia to Improve Walking Ability in Adult Patients with MS
- May 11, 2011 - MS Drug's Therapeutic, Adverse Effects Separated in New Study
- May 6, 2011 - Discovery Demonstrates Potential MS Therapy Could Kill Brain Cells
- May 3, 2011 - Adeona's Multiple Sclerosis Clinical Trial Receives $1,594,553 Grant
- April 28, 2011 - Merck Serono Provides $1.5M Grant to Massachusetts General Hospital
- April 25, 2011 - XenoPort Announces FDA Agreement on a Special Protocol Assessment for a Pivotal Phase 3 Clinical Trial of Arbaclofen Placarbil for Spasticity in MS Patients
- April 21, 2011 - UCSF Study Revisits First Clinical Trial to Treat Multiple Sclerosis Decades Later
- April 19, 2011 - Biogen Idec Receives Positive Opinion from the CHMP and Authorisation from Health Canada on Avonex Pen
- April 18, 2011 - Scripps Research Scientists Develop Compound That Effectively Halts Progression of Multiple Sclerosis
- April 18, 2011 - CHMP Recommends Updating Tysabri Labeling with anti-JC Virus Antibody Status as a Third Factor to Further Stratify Risk of PML
- April 12, 2011 - Oral Laquinimod for Multiple Sclerosis Treatment Significantly Reduced Disease Activity and Disability Progression While Providing Good Safety and Tolerability
- April 11, 2011 - Novartis Therapy Gilenyatm Reduced the Risk of MS Disability Progression Regardless of Treatment History Or Disease Severity, New Analysis Shows
- April 11, 2011 - Acorda Therapeutics Presents New AMPYRA (dalfampridine) Data Analyses on Walking Improvement in Multiple Sclerosis at AAN Annual Meeting
- April 11, 2011 - Biogen Idec Announces Positive Top-Line Results from the First Phase 3 Trial Investigating Oral BG-12 (DIMETHYL FUMARATE) in Multiple Sclerosis
- April 4, 2011 - Avanir Pharmaceuticals Announces Filing of IND for AVP-923 for the Treatment of Central Neuropathic Pain in Patients with Multiple Sclerosis
- March 28, 2011 - Adeona's Multiple Sclerosis Trial Receives $409,426 Grant
- March 22, 2011 - Sativex recommended for approval in all six European countries
- March 21, 2011 - Novartis Receives European Commission Approval for Gilenya, the First Oral Multiple Sclerosis Treatment for Use in the EU
- March 16, 2011 - CIGNA and EMD Serono Team to Fight Multiple Sclerosis Under First Outcomes-Based Specialty Medication Contract
- March 14, 2011 - Purdue Research May Lead to Therapy That Delays Onset, Reduces Severity of MS Symptoms
- March 10, 2011 - First oral treatment for people with multiple sclerosis approved in Canada
- March 7, 2011 - Stem Cell Therapeutics Corp. Announces Commencement of MS Research Program
- March 2, 2011 - EMD Serono Receives Complete Response Letter From FDA on Cladribine Tablets New Drug Application
- February 16, 2011 - Reimbursement granted for Sativex in Spain, for the treatment of spasticity in multiple sclerosis
- February 10, 2011 - Merck Serono Launches UniteMS.net - A Pioneering Social Network and Online Resource for the Multiple Sclerosis Community
- February 3, 2011 - New Analysis Published in Multiple Sclerosis Journal Recommends Intrathecal Baclofen (Itb) Therapy for Ms Patients Suffering From Spasticity
- January 28, 2011 - Receptos Initiates Clinical Trials for S1P1 Agonist Program, Aimed at Multiple Sclerosis
- January 21, 2011 - Novartis International AG (CH) - Novartis Gains Positive CHMP Opinion for Gilenya, First Oral Multiple Sclerosis Treatment Recommended for Approval in the European Union
- January 21, 2011 - Acorda Therapeutics Statement on European CHMP Decision on Fampyra
- January 21, 2011 - Merck Serono Announces Outcome of Its Request for Reexamination of CHMP Opinion for Cladribine Tablets in MS
- January 10, 2011 - Safety Alert: Certain Alcohol Pads/Swabs Recalled by FDA - anyone taking injectable medication should check package to see if they were made by Triad Group
- January 5, 2011 - Opexa Successfully Completes End-of Phase 2 Meetings with FDA; In Position for Pivotal Study of Tovaxin
|
